Cyclin dependent Kinase News and Research

RSS

Dormant HIV reservoirs could be killed with RNA switch

Researchers from the University of California San Diego School of Medicine have found cellular triggers within the immune cells that could be controlled in order to kill dormant HIV-1 reservoirs in individuals with HIV-1.

25 Sep 2019

Study searches for the origins of depressive symptoms in Huntington's disease

About 40% of the affected patients with Huntington's disease -a neurodegenerative pathology- show depression symptoms, even in early stages before the apparition of the typical motor symptoms of the disease.

31 May 2019

Study sheds light on design of pharmacological strategies to treat depression in Huntington's disease

About 40 % of the affected patients with Huntington's disease -a neurodegenerative pathology- show depression symptoms, even in early stages before the apparition of the typical motor symptoms of the disease.

31 May 2019

Study: Male and female differences in fear memory is attributed to Cdk5 gene

In a mouse model of traumatic memory, male mice recall fear-related memories better than female mice, according to a study in Biological Psychiatry. The difference between sexes was attributed to a gene important for creating fear memories and stress behavior, called cyclin dependent kinase 5, which was naturally activated in male but not in female mice.

18 Jan 2019

CDK2 protein plays key role in heart damage caused by doxorubicin, finds study

A new study by Washington State University researchers suggests that a protein called CDK2 plays a critical role in heart damage caused by doxorubicin, a commonly used chemotherapy drug.

8 Nov 2018

Novel drug extends survival for women with HR-positive metastatic breast cancer

The drug palbociclib, used in combination with standard treatment, improved survival for women with hormone receptor-positive metastatic breast cancer, according to a large phase III clinical trial.

24 Oct 2018

Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy

Treatment with the cyclin dependent kinase 4/6 inhibitor palbociclib achieves a clinically meaningful improvement in overall survival in patients with hormone receptor positive human epidermal growth factor receptor-2 negative advanced breast cancer that has relapsed or progressed on hormonal therapy, according to the final analysis of overall survival results from the PALOMA-3 study reported at ESMO 2018.

23 Oct 2018

Drugs approved for breast cancer treatment are effective and well tolerated in men

There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer and two further studies to be reported at ESMO 2018.

23 Oct 2018

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias.

4 Oct 2018

Canadian researchers uncover new molecular mechanism to stop proliferation of cancer cells

Canadian researchers have discovered a new and direct molecular mechanism to stop cancer cells from proliferating. In the prestigious journal Nature Cell Biology, scientists from Université de Montréal show that a disruption of a fine balance in the composition of ribosomes (huge molecules that translate the genetic code into proteins) results in a shutdown of cancer cell proliferation, triggering a process called senescence.

26 Jun 2018

Coffee and the heart – four strong cups a day is beneficial finds study

According to a new study four cups of strong coffee might be the amount that would keep the hearts of older adults healthy. The latest study titled, “CDKN1B/p27 is localized in mitochondria and improves respiration-dependent processes in the cardiovascular system—New mode of action for caffeine,” was published on 21st of June 2018 in the journal PLOS Biology.

25 Jun 2018

Molecular inhibitors found to arrest tumor cell proliferation in lung cancer and mesothelioma

Inhibition of the oncogenic kinase AKT, a key protein governing the cell cycle, was found to arrest cancer cell proliferation and triggered their programmed death by apoptosis.

2 Apr 2018

Ground-breaking new breast cancer drugs have manageable toxicity profile for most patients

A ground-breaking new class of oral drugs for treating breast cancer, known as cyclin-dependent kinase (CDK) inhibitors, are generally well-tolerated, with a manageable toxicity profile for most patients.

13 Jul 2017

Collaborative effort to develop rare disease patient registries

The Orphan Disease Center in the Perelman School of Medicine at the University of Pennsylvania will collaborate with Pulse Infoframe Inc., a medical informatics company, to develop rare disease patient registries aimed at enabling international collaboration to better understand these diseases, as well as accelerate and improve clinical studies to develop new therapies.

31 May 2017

Fresh insights into immune cell could signal new approach to treating life-threatening lung condition

Fresh insights into a life-threatening lung condition triggered by blood poisoning could signal a new approach to treating the disease, researchers found.

3 Nov 2016

NCATS scientists identify promising compounds effective in inhibiting Zika virus replication

Researchers at the National Center for Advancing Translational Sciences recently identified compounds that potentially can be used to inhibit Zika virus replication and reduce its ability to kill brain cells.

29 Aug 2016

Scientists develop model using transformed stem cells to accelerate screening of drugs for rare cancers

Researchers at the Johns Hopkins Kimmel Cancer Center say they have developed a system that uses transformed human stem cells to speed up screening of existing drugs that might work against rare brain and other cancers.

2 Aug 2016

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy.

23 Feb 2016

LouLou Foundation, Penn Med set up Program of Excellence to develop treatments for children with CDKL5

The London-based LouLou Foundation and the Orphan Disease Center of the Perelman School of Medicine at the University of Pennsylvania have established a Program of Excellence to develop effective treatments for children with CDKL5, a rare X-chromosome-linked genetic disorder that causes severe neuro-developmental impairment and early-onset, difficult-to-control seizures.

8 Feb 2016

UT Southwestern researchers reveal how CDK4/6-inhibitors alter pancreatic cancer cell metabolism

UT Southwestern Medical Center researchers have found that cancer drugs known as CDK4/6-inhibitors alter the metabolism of pancreatic cancer cells, revealing a biologic vulnerability that could be exploited for therapeutic gain.

22 Jan 2016